This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

Incorporating Immunotherapy Into Treatment for MSI-H/dMMR Colorectal Cancer:  Latest Updates on Testing, Treatment, and irAE Management

Incorporating Immunotherapy Into Treatment for MSI-H/dMMR Colorectal Cancer: Latest Updates on Testing, Treatment, and irAE Management

Format

Webcast

Time to Complete

1.25 hours

Released

February 27, 2019

Expires

February 27, 2020
Add to Queue


Maximum Credits

1.25 / AMA PRA Category 1 CreditsTM

Accredited Provider



This activity is provided by Paradigm Medical Communications, LLC.

Commercial Supporter

This activity is supported by an educational grant from Bristol-Myers Squibb.

Program Description

Although immunotherapy has been available for other solid tumors since 2011, several immunotherapy regimens were recently approved for the treatment of relapsed/refractory colorectal cancer (CRC) with high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR), ushering in a new treatment paradigm. This activity will introduce information about MSI and MMR in CRC; help clinicians formulate treatment plans for advanced CRC using immune checkpoint inhibition, alone or in combination with other therapies, based on the latest clinical trial data; and discuss evidence-based strategies to monitor for, recognize, and effectively manage potential irAEs associated with immune checkpoint inhibition.

Table of Contents

  • Introduction to Microsatellite Instability (MSI) and Mismatch Repair (MMR) in CRC—Michael J. Overman, MD
  • Case 1: Patient With Metastatic CRC—Richard Kim, MD
  • Case 2: Patient With Relapsed/Refractory CRC With MSI-H/dMMR—Michael J. Overman, MD
  • Case 3: Patient With CRC Receiving Immunotherapy Develops an irAE—Johanna Bendell, MD
  • Faculty Roundtable Discussion and Conclusion—Faculty Panel

Intended Audience

This activity has been designed to address the educational needs of oncologists who treat patients with colorectal cancer (CRC). The activity may also benefit other oncology healthcare professionals involved in the management of patients with CRC.

Educational Objectives

Upon proper completion of this activity, participants should be better able to:

  • Use results of MSI/dMMR testing to determine appropriate management of advanced CRC
  • Formulate treatment plans for advanced CRC using immune checkpoint inhibition, alone or in combination with other therapies, based on the latest clinical trial data
  • Apply evidence-based strategies to monitor for, recognize, and effectively manage potential irAEs associated with immune checkpoint inhibition

Conflict of Interest Disclosure Policy

Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.

Faculty

In accordance with Accreditation Council for Continuing Medical Education requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.

Michael J. Overman, MD (Chair)
Professor
Department of Gastrointestinal Medical Oncology
Center Medical Director, Ambulatory Treatment Center
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Dr. Overman discloses the following:
Grant/Research Support: AstraZeneca; Bristol-Myers Squibb Company; Merck & Co, Inc
Retained Consultant: AstraZeneca; Bristol-Myers Squibb Company; Roche

Richard Kim, MD
Section Chief of GI Medical Oncology
Department of Gastrointestinal Oncology
Moffitt Cancer Center
Associate Professor
Division of Medical Oncology
University of South Florida College of Medicine
Tampa, FL

Dr. Kim discloses the following:
Grant/Research Support: Bayer HealthCare; Bristol-Myers Squibb Company; Eisai, Inc
Retained Consultant: Bayer HealthCare; Bristol-Myers Squibb Company; Eisai, Inc
Speakers Bureau: Eli Lilly and Company

Johanna Bendell, MD
Chief Development Officer
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, TN

Dr. Bendell has no financial relationships to disclose.

Accredited Provider Disclosure

Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.

Peer Reviewer Disclosure

Peer reviewer, Marwan G. Fakih, MD discloses the following:
Retained Consultant: Array BioPharma; Seattle Genetics, Inc
Speakers Bureau: Amgen Inc

Credit

1.25

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Credit Information

PA Continuing Education
PAs may claim a maximum of 1.25 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM  from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM  from organizations accredited by ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.

Disclaimer

This CME activity represents the views and opinions of the individual faculty members, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.

Instructions

To receive a CME certificate of participation, you should:

  • Follow the "Start Activity" button to go to the Paradigm Medical Communications website, where you will complete the pre-activity assessment
  • View the online activity in its entirety
  • Complete and submit the online post-activity assessment and evaluation
A certificate of participation will be available for download/printing immediately following your successful completion of the post-activity assessment and evaluation. Your certificate will be saved on the Paradigm Medical Communications website and will not be available in your myCME CME History.

For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949.

There is no fee required for participation in this activity.

Terms of Use and Privacy Policy

Disclaimer
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. Any views or opinions presented are solely those of the faculty, and do not necessarily represent those of Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.

Privacy policy
Paradigm Medical Communications, LLC is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.

Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.

myCME privacy policy

Technical Requirements

Hardware/Software Requirements
This certified CME activity is designed using HTML5 media controls. As you navigate the video using the supplied controls, the slides will sync to the speaker.

For Desktops (Windows/Mac)
Internet Explorer 9 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher

For Tablets (iPad/Android/Surface)
iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher

Technical Support: If you have any technical problems or playback issues, please email us at contactus@paradigmmc.com.

Copyright

© 2019 Paradigm Medical Communications, LLC, except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.
Add to Queue